Importantly, when we determined the disease-free survival (DFS) of patients after curative tumor resection, we could separate the patients using the TGM2 expression level at diagnosis: patients with strong TGM2 expression developed tumor recurrence more frequently than patients with weak or moderate TGM2 staining index (Fig. 2B, p = 0.0001). This evidence concerns the gene TGM2 and neoplasm.